I keep running into “best peptide stack for men” threads, and the answers are usually either hype or someone’s personal log. I’d like to understand what’s supported by published research versus what’s repeated because it sounds plausible. Here’s where I’ve got to.
Human trial data I could find
Semaglutide: STEP 1 (Wilding et al., NEJM, 2021), a phase 3 obesity trial. Women were the majority of participants, so I’m curious how men-specific results are interpreted.
Tirzepatide: SURMOUNT-1 (Jastreboff et al., NEJM, 2022), also phase 3, same question about the sex breakdown.
Tesamorelin: Falutz et al., NEJM, 2007, on visceral fat in HIV-associated lipodystrophy. Unclear how far that generalizes.
Interesting but thinner
BPC-157 / TB-500: Lots of animal data, very little controlled human data that I can find.
GH secretagogues (ipamorelin, CJC-1295, etc.): Solid mechanistic work, but long-term human outcome data seems limited.
Kisspeptin / gonadorelin: HPG-axis research in men exists, but I’m unsure how much is clinical vs. mechanistic.
What I’m struggling with
“Stack” assumes combinations behave additively, but I haven’t found much peer-reviewed work on combinations at all. Most of it looks like extrapolation from single-compound studies.
How do you judge study quality (sample size, controls, funding)?
For your specific question, I'd separate evidence for a drug from evidence for a stack. STEP 1 and SURMOUNT-1 randomized people to one medicine versus placebo for obesity; they don't test a 'men's stack.' The male-subgroup estimate and its confidence interval matter more than the share of men enrolled. A claim that men respond differently also needs a prespecified sex-interaction test, not just two subgroup percentages.
The tesamorelin trial measured visceral fat in people with HIV-associated lipodystrophy. That's a real human result, but it doesn't establish a general anti-aging or stacking benefit. For a combination, I'd want a controlled trial with each ingredient alone, the combination, and a comparator, plus a prespecified outcome and enough follow-up for harms. Until then, adding single-agent results together is a hypothesis. I write for PeptideWHY, for disclosure; the study design matters more to me than a catchy stack name.
